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BENIGN prostate hypertrophy (BPH) is the most
common benign tumor in men due to obstruction
of the urethra and, finally, uremia. Malondialdehyde
(MDA) is a product derived from peroxidation of
polyunsaturated fatty acids and related esters. Evalua-
tion of MDA in serum represents a non-invasive
biomarker of oxidative stress. Prostate-specific anti-
gen (PSA) is a sensitive marker for prostatic hyper-
trophy and cancer. We analyzed MDA serum levels to
evaluate the oxidative stress in BPH. To this end, 22
BPH patients and 22 healthy donors were enrolled.
Data show an increase of MDA level in BPH patients
and a positive correlation between PSA and MDA
levels. In conclusion, we describe a previously un-
known relationship between PSA and MDA as an
index of inflammation and oxidative stress in BPH.
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The most dramatic organic manifestation of andro-
pause in terms of a decrease in quality of life is
benign prostate hypertrophy (BPH), in its ultimate
consequences a life-threatening condition due to
obstruction of the urethra and, finally, uremia.
1 The
process of prostatic hypertrophy involves all four
major cell types in the prostate (smooth muscle cells,
fibroblast, acinar and basal epithelial cells) and a
variety of hormones, growth factors, and their
receptors.
2 There is much evidence to suggest that
benign prostatic hypertrophy is an endocrine dis-
ease.
2 In the adult male, testicular androgens regulate
development, growth and functional maintenance of
the prostate gland. Androgens regulate prostate-
specific antigen (PSA) secretion by acinar epithelial
cells.
2 PSA, a serine protease synthesized by benign
and malignant prostatic epithelium, is a sensitive
serum marker for prostatic hypertrophy and cancer.
In fact, increased PSA levels are often seen in
carcinomas of the prostate, but have also been
reported in benign inflammatory disorders of the
prostate.
3 Lipid peroxidation is a well-established
mechanism of cellular injury in both plants and
animals. This process, leading to the production of
lipid peroxides and their byproducts, and ultimately
to the loss of membrane function and integrity, is
widely accepted to be involved in the pathogenesis
of several human diseases. MDA is an end-product
derived from peroxidation of polyunsaturated fatty
acids and related esters. In contrast to free radicals,
aldehydes are relatively stable and therefore able to
diffuse within or out of the cell and to attack targets
distant from the site of original free-radical-initiated
events. Furthermore, MDA does not just reflect lipid
peroxidation, but is also a byproduct of cyclooxy-
genase activity in platelets, and persistent platelet
activation is a common feature of many clinical
syndromes associated with enhanced lipid peroxida-
tion. Thus, measurement of MDA levels in plasma or
serum provides a convenient in vivo index of lipid
peroxidation and represents a non-invasive biomar-
ker of oxidative stress often clinically employed to
investigate radical-mediated physiological and patho-
logical conditions.
4 In the light of these findings, we
analyzed MDA serum levels in order to clarify the
oxidative stress in benign prostatic hyperplasia.
Moreover, we investigated whether a correlation
exists between MDA and PSA serum levels.
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127To this end, 22 BPH patients (mean age, 65.8 years;
range, 56/79 years), selected on the basis of trans-
rectal ultrasound-guided sextant biopsies of the
prostate, were enrolled in this study. Twenty-two
healthy donors (mean age, 62.1 years; range, 55/76
years) were also enrolled as a control group. Patients
and healthy donors signed an informed consent
form. Sera were obtained from peripheral blood
allowed to clot at room temperature for 2 h,
separated by centrifugation at 200/g for 15 min in
a 4235 A (ALC Int. S.r.L., Milan, Italy) centrifuge, and
stored at  /808C until use. PSA levels were measured
with the Hybritech Tandem-R assay with one kit at
one side. The inter-assay and intra-assay coefficients
of variation of these assays were B/7% and B/6%,
respectively. Plasma MDA levels were measured by
means of a colorimetric assay specific for MDA and
carried out using a commercially available kit (Cal-
biochem-Novabiochem Corporation, La Jolla, CA,
USA). This method employs a chromogenic reagent,
which reacts with MDA at 458C, yielding a stable
chromophore with maximal absorbance at 586 nm.
Differences in serum MDA levels were assessed by
one-way analysis of variance and the Student/New-
man/Keults test. Data were expressed as the mean9 /
standard deviation. A value p B/ 0.05 was considered
significant. Correlation between PSA and MDA values
were calculated with the Spearman rank test. All data
were analyzed using the Stat View SE program
(Abacus, Berkeley, CA, USA). The mean serum PSA
level was 14.349 /11.85 ng/ml, varying from 3.80 to
57.20 ng/ml. Serum MDA levels of BPH patients were
significantly higher than those of healthy donors
(HD) (2.129 /0.44 versus 0.979 /0.30 nmol/ml). These
data represent the first evidence of circulating MDA
level increase in BPH patients and confirm the well-
known involvement of oxidative stress in BPH.
Programmed death of cells by apoptosis is a
protective mechanism of the organism against accu-
mulation and spread of defective cells. A decreased
susceptibility of senescent cells in vitro and in vivo to
apoptosis by oxidative stress has been observed.
5
Highly reactive aldehydes (e.g. 4-hydroxynonenal,
MDA), products of the lipid peroxidation, are capable
of modifying both DNA and proteins, resulting in
mutagenic, genotoxic and cytotoxic events. There-
fore, high levels of MDA, such as of other reactive
aldehydes, may explain DNA base modifications
demonstrated not only in prostate cancer, but also
in BPH epithelium. As shown in Fig. 1, analyzed data
of our study show that MDA levels strongly correlate
with PSA levels in BPH patients (rho/0.583; p/
0.0076). Serum PSA is the most useful parameter for
determining the diagnosis of prostate cancer and the
malignant potential of recurrent tumor after radical
prostatectomy. Its values are also increased in BPH.
Although the high MDA circulating levels observed in
BPH patients strictly demonstrate only the existence
of an oxidative stress in this pathological condition,
in the light of the strong positive correlation found
between PSA and MDA levels in our study, we can
speculate that increased circulating MDA levels might
be considered a useful marker of lipid peroxidation
and inflammation of prostate epithelium. Moreover,
the finding of very high MDA levels in a BPH patient
may be considered predictive for prostate cancer. In
conclusion, here we describe for the first time a
previously unknown relationship between PSA and
MDA as an index of inflammation and oxidative stress
in BPH patients. Furthermore, our preliminary find-
ings suggest that an antioxidant such as vitamin E,
lycopene or selenium may have a role in preventing
prostate cancer progression.
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FIG. 1. Correlation between MDA and PSA in BPH.
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